Manchester Innovation Ltd.
Manchester Innovation Ltd.'s role goes beyond commercializing intellectual property generated by the university and managing the biotechnology incubator building on the university's behalf. Where some other universities' technology transfer initiatives stop at helping with the formation and financing of spin-out companies, MIL aims to provide its spin-outs with ongoing help to develop into successful enterprises.
You may also be interested in...
There are currently no effective pharmacological treatments to prevent scarring following trauma or surgery. Renovo, a spin-off from the University of Manchester, was set up two years ago with this market in mind. Renovo has two anti-scarring compounds in clinical trials, based on Transforming Growth Factor Beta 3, which appears to promote healing without scarring in embryos, and an antagonist of Transforming Growth Factor Beta 1 and Beta 2, growth factors which appear to be associated with scarring in adults.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.